Bortezomib Reinduction Chemotherapy in High-Risk ALL in First Relapse: A Report from the Children’s Oncology Group

While survival in paediatric acute lymphoblastic leukaemia (ALL) is excellent, survival following relapse is poor. Previous studies suggest proteasome inhibition with chemotherapy improves relapse ALL response rates. This phase 2 Children’s Oncology Group study tested the hypothesis that adding the...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Br J Haematol
Huvudupphovsmän: Horton, Terzah M., Whitlock, James A., Lu, Xiaomin, O’Brien, Maureen M., Borowitz, Michael J., Devidas, Meenakshi, Raetz, Elizabeth A., Brown, Patrick A., Carroll, William L., Hunger, Stephen P.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2019
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6606340/
https://ncbi.nlm.nih.gov/pubmed/30957229
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.15919
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk